10 completed. 10 Phase 1, 3 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 10 | Completed 10 |
| Phase 2 | 3 | Completed 3 |
Follow Malignant Solid Neoplasm: new trials by email Literature Review of Malignant Solid Neoplasm trials Research Report on Malignant Solid Neoplasm
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Psilocybin Combined With Multidisciplinary Palliative Care in Demoralized Cancer Survivors With Chronic Pain Psilocybin, Psychotherapy, Quality-of-Life Assessment - Hematopoietic and Lymphoid Cell Neoplasm, Malignant Solid Neoplasm | Phase 1 | Completed | Emory University | 11 | 2022-11-01 | 2025-07-23 |
| Development of a Digital Tool, MyInspiration, for the Improvement of Spiritual Well-Being in Patients with Cancer Internet-Based Intervention - Malignant Solid Neoplasm | Phase 1 | Completed | Ohio State University Comprehensive Cancer Center | 52 | 2022-07-01 | 2024-10-08 |
| Testing the Addition of an Anti-cancer Drug, Entinostat, to the Usual Chemotherapy and Immunotherapy Treatment (Atezolizumab, Carboplatin and Etoposide) for Previously Untreated Aggressive Lung Cancer That Has Spread Atezolizumab, Carboplatin, Entinostat - Extensive Stage Lung Small Cell Carcinoma, Malignant Solid Neoplasm | Phase 1 | Completed | National Cancer Institute (NCI) | 3 | 2021-04-27 | 2025-10-03 |
| Leflunomide for the Treatment of Severe COVID-19 in Patients With a Concurrent Malignancy Best Practice, Leflunomide, Placebo Administration - Hematopoietic and Lymphoid Cell Neoplasm, Malignant Solid Neoplasm | Phase 1 / Phase 2 | Completed | City of Hope Medical Center | 2 | 2021-01-07 | 2024-07-03 |
| Ibrutinib for the Treatment of COVID-19 in Patients Requiring Hospitalization Best Practice, Ibrutinib - Aplastic Anemia, Hematopoietic and Lymphoid Cell Neoplasm | Phase 1 | Completed | Jennifer Woyach | 10 | 2020-10-23 | 2023-12-26 |
| Alisertib and Pembrolizumab for the Treatment of Patients With Rb-deficient Head and Neck Squamous Cell Cancer Alisertib, Pembrolizumab - Head and Neck Squamous Cell Carcinoma, Malignant Solid Neoplasm | Phase 1 / Phase 2 | Completed | M.D. Anderson Cancer Center | 24 | 2020-09-15 | 2025-05-20 |
| Pro-Active Genetic Testing in Patients With Solid Tumors, Inherit Study Biospecimen Collection, Genetic Counseling, Genetic Testing - Breast Carcinoma, Digestive System Neoplasm | Phase 1 | Completed | Mayo Clinic | 230 | 2020-06-29 | 2023-07-24 |
| Liposomal Irinotecan and Veliparib in Treating Patients With Solid Tumors Ferumoxytol, Irinotecan Sucrosofate, Laboratory Biomarker Analysis - Malignant Solid Neoplasm | Phase 1 | Completed | National Cancer Institute (NCI) | 18 | 2017-05-31 | 2025-02-10 |
| Pembrolizumab and Stereotactic Body Radiation Therapy or Non-Stereotactic Wide-Field Radiation Therapy in Treating Patients With Non-small Cell Lung Cancer 3-Dimensional Conformal Radiation Therapy, Intensity-Modulated Radiation Therapy, Laboratory Biomarker Analysis - Malignant Solid Neoplasm, Metastatic Lung Non-Small Cell Carcinoma | Phase 1 / Phase 2 | Completed | M.D. Anderson Cancer Center | 124 | 2015-09-17 | 2026-05-15 |
| Nab-Paclitaxel and Bevacizumab in Treating Patients With Unresectable Stage IV Melanoma or Gynecological Cancers Bevacizumab, Laboratory Biomarker Analysis, Nab-paclitaxel - Cervical Adenocarcinoma, Cervical Adenosarcoma | Phase 1 | Completed | Mayo Clinic | 43 | 2014-02-24 | 2024-07-26 |
Hematologic Neoplasms (3) · Brain Neoplasms (2) · Head and Neck Neoplasms (2) · Anemia, Aplastic (1) · Breast Neoplasms (1) · Carcinoma, Non-Small-Cell Lung (1) · Central Nervous System Neoplasms (1) · Digestive System Neoplasms (1) · Monoclonal Gammopathy of Undetermined Significance (1) · Myelodysplastic Syndromes (1) · Neoplasms, Unknown Primary (1) · Squamous Cell Carcinoma of Head and Neck (1) · Urogenital Neoplasms (1)
Neoplasms (7) · Neoplasms by Site (7) · Hematologic Diseases (3) · Hemic and Lymphatic Diseases (3) · Brain Diseases (2) · Central Nervous System Diseases (2) · Nervous System Diseases (2) · Nervous System Neoplasms (2) · Anemia (1) · Blood Protein Disorders (1) · Bone Marrow Diseases (1) · Bone Marrow Failure Disorders (1) · Breast Diseases (1) · Bronchial Neoplasms (1) · Carcinoma (1)
Practice Guidelines as Topic (2) · Standard of Care (2) · pembrolizumab (2) · 130-nm albumin-bound paclitaxel (1) · Albumin-Bound Paclitaxel (1) · Bevacizumab (1) · Carboplatin (1) · Disulfides (1) · Etoposide (1) · Ferrosoferric Oxide (1) · Genetic Counseling (1) · Genetic Testing (1) · Immunoglobulin G (1) · Leflunomide (1) · MLN 8237 (1)
M.D. Anderson Cancer Center (2) · Mayo Clinic (2) · National Cancer Institute (NCI) (2) · City of Hope Medical Center (1) · Emory University (1) · Jennifer Woyach (1) · Ohio State University Comprehensive Cancer Center (1)
United States (10)
Ali J. Zarrabi, MD (1) · Faye M Johnson, MD (1) · James Welsh (1) · Jennifer A Woyach, MD (1) · Matthew S. Block, M.D., Ph.D. (1) · Niloy J Samadder (1) · Ryan D Gentzler (1) · Sanjeet S Dadwal (1) · Susan E Bates (1) · Timothy M Pawlik, MD (1)
PMID 31996395, PMID 33051340, PMID 33096027, PMID 34749885, PMID 37010988, PMID 37555284
P30CA033572 (1), P30CA138292 (1), UM1CA186691 (1), ZIABC011078 (1)